Gevorkian G, Soler C, Viveros M, Padilla A, Govezensky T, Larralde C
Instituto de Investigaciones, Biomedicas, Universidad Nacional Autonoma de Mexico, Mexico, D.F.
Clin Diagn Lab Immunol. 1996 Nov;3(6):651-3. doi: 10.1128/cdli.3.6.651-653.1996.
The reactivities of 1,172 serum samples obtained from asymptomatic human immunodeficiency virus type 1 (HIV-1)-positive and HIV-1-negative individuals residing in Mexico to a synthetic disulfide-looped peptide from the HIV-1 gp41 (amino acids 602 to 616 [IWGCSGKLICTTAVP] were examined by an enzyme-linked immunoadsorbent assay (ELISA) procedure. Antibodies to the synthetic peptide were detected in 261 of 268 serum samples from HIV-positive individuals (sensitivity, 97.4%). The peptide also reacted with 12 of 904 serum samples from control HIV-negative individuals (specificity, 98.7%). Western blots (immunoblots) of four of the seven serum samples that produced false-negative results in the ELISA showed that three of them reacted weakly with gp41 and strongly with gp120, p55, and/or p24. Potential diagnostic difficulties raised by the reported C1q binding capacity of this peptide were also evaluated: few and weak false-positive results were found among sera from patients with rheumatoid arthritis (1 of 31) and neurocysticercosis (2 of 111). In fact, strong reactivity with the peptide spotted an undetected HIV infection underlying clinical neurocysticercosis.
采用酶联免疫吸附测定(ELISA)方法,检测了从墨西哥无症状人类免疫缺陷病毒1型(HIV-1)阳性和HIV-1阴性个体获得的1172份血清样本对HIV-1 gp41合成二硫键环化肽(氨基酸602至616 [IWGCSGKLICTTAVP])的反应性。在268份HIV阳性个体的血清样本中,有261份检测到了针对合成肽的抗体(敏感性为97.4%)。该肽还与904份对照HIV阴性个体的血清样本中的12份发生反应(特异性为98.7%)。在ELISA中产生假阴性结果的7份血清样本中,有4份的蛋白质印迹(免疫印迹)显示,其中3份与gp41反应较弱,但与gp120、p55和/或p24反应强烈。还评估了该肽所报道的C1q结合能力引发的潜在诊断困难:在类风湿性关节炎患者(31份样本中的1份)和神经囊尾蚴病患者(111份样本中的2份)的血清中发现了少量且微弱的假阳性结果。事实上,与该肽的强烈反应揭示了临床神经囊尾蚴病潜在的未被检测到的HIV感染。